These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 27745917

  • 1. Prospective evaluation of the molecular effects of metformin on the endometrium in women with newly diagnosed endometrial cancer: A window of opportunity study.
    Soliman PT, Zhang Q, Broaddus RR, Westin SN, Iglesias D, Munsell MF, Schmandt R, Yates M, Ramondetta L, Lu KH.
    Gynecol Oncol; 2016 Dec; 143(3):466-471. PubMed ID: 27745917
    [Abstract] [Full Text] [Related]

  • 2. Measuring the biological effect of presurgical metformin treatment in endometrial cancer.
    Sivalingam VN, Kitson S, McVey R, Roberts C, Pemberton P, Gilmour K, Ali S, Renehan AG, Kitchener HC, Crosbie EJ.
    Br J Cancer; 2016 Feb 02; 114(3):281-9. PubMed ID: 26794276
    [Abstract] [Full Text] [Related]

  • 3. Effects of metformin on endometrial cancer cell growth in vivo: a preoperative prospective trial.
    Mitsuhashi A, Kiyokawa T, Sato Y, Shozu M.
    Cancer; 2014 Oct 01; 120(19):2986-95. PubMed ID: 24917306
    [Abstract] [Full Text] [Related]

  • 4. Metformin inhibits growth of eutopic stromal cells from adenomyotic endometrium via AMPK activation and subsequent inhibition of AKT phosphorylation: a possible role in the treatment of adenomyosis.
    Xue J, Zhang H, Liu W, Liu M, Shi M, Wen Z, Li C.
    Reproduction; 2013 Oct 01; 146(4):397-406. PubMed ID: 23904524
    [Abstract] [Full Text] [Related]

  • 5. Metformin is associated with reduced cell proliferation in human endometrial cancer by inbibiting PI3K/AKT/mTOR signaling.
    Zhao Y, Sun H, Feng M, Zhao J, Zhao X, Wan Q, Cai D.
    Gynecol Endocrinol; 2018 May 01; 34(5):428-432. PubMed ID: 29182407
    [Abstract] [Full Text] [Related]

  • 6. Antiproliferative and metabolic effects of metformin in a preoperative window clinical trial for endometrial cancer.
    Schuler KM, Rambally BS, DiFurio MJ, Sampey BP, Gehrig PA, Makowski L, Bae-Jump VL.
    Cancer Med; 2015 Feb 01; 4(2):161-73. PubMed ID: 25417601
    [Abstract] [Full Text] [Related]

  • 7. Metformin inhibits 17β-estradiol-induced epithelial-to-mesenchymal transition via βKlotho-related ERK1/2 signaling and AMPKα signaling in endometrial adenocarcinoma cells.
    Liu Z, Qi S, Zhao X, Li M, Ding S, Lu J, Zhang H.
    Oncotarget; 2016 Apr 19; 7(16):21315-31. PubMed ID: 26824324
    [Abstract] [Full Text] [Related]

  • 8. Insulin-Like Growth Factor 1/Mammalian Target of Rapamycin and AMP-Activated Protein Kinase Signaling Involved in the Effects of Metformin in the Human Endometrial Cancer.
    Cai D, Sun H, Qi Y, Zhao X, Feng M, Wu X.
    Int J Gynecol Cancer; 2016 Nov 19; 26(9):1667-1672. PubMed ID: 27654259
    [Abstract] [Full Text] [Related]

  • 9. LY294002 and metformin cooperatively enhance the inhibition of growth and the induction of apoptosis of ovarian cancer cells.
    Li C, Liu VW, Chan DW, Yao KM, Ngan HY.
    Int J Gynecol Cancer; 2012 Jan 19; 22(1):15-22. PubMed ID: 22080879
    [Abstract] [Full Text] [Related]

  • 10. Jupiter microtubule-associated homolog 1 (JPT1): A predictive and pharmacodynamic biomarker of metformin response in endometrial cancers.
    Bateman NW, Teng PN, Hope E, Hood BL, Oliver J, Ao W, Zhou M, Wang G, Tommarello D, Wilson K, Litzy T, Conrads KA, Hamilton CA, Darcy KM, Casablanca Y, Maxwell GL, Bae-Jump V, Conrads TP.
    Cancer Med; 2020 Feb 19; 9(3):1092-1103. PubMed ID: 31808620
    [Abstract] [Full Text] [Related]

  • 11. PRE-surgical Metformin In Uterine Malignancy (PREMIUM): a Multi-Center, Randomized Double-Blind, Placebo-Controlled Phase III Trial.
    Kitson SJ, Maskell Z, Sivalingam VN, Allen JL, Ali S, Burns S, Gilmour K, Latheef R, Slade RJ, Pemberton PW, Shaw J, Ryder WD, Kitchener HC, Crosbie EJ.
    Clin Cancer Res; 2019 Apr 15; 25(8):2424-2432. PubMed ID: 30563932
    [Abstract] [Full Text] [Related]

  • 12. Anti-diabetic doses of metformin decrease proliferation markers in tumors of patients with endometrial cancer.
    Laskov I, Drudi L, Beauchamp MC, Yasmeen A, Ferenczy A, Pollak M, Gotlieb WH.
    Gynecol Oncol; 2014 Sep 15; 134(3):607-14. PubMed ID: 24972190
    [Abstract] [Full Text] [Related]

  • 13. Metformin Promotes Anti-tumor Biomarkers in Human Endometrial Cancer Cells.
    Pabona JMP, Burnett AF, Brown DM, Quick CM, Simmen FA, Montales MTE, Liu SJ, Rose T, Alhallak I, Siegel ER, Simmen RC.
    Reprod Sci; 2020 Jan 15; 27(1):267-277. PubMed ID: 32046384
    [Abstract] [Full Text] [Related]

  • 14. Immunolocalization of ERK1/2 and p-AKT in normal endometrium, endometrial hyperplasia, and early and advanced stage endometrioid endometrial adenocancer and their prognostic significance in malignant group.
    Gungorduk K, Ertas IE, Sahbaz A, Ozvural S, Sarica Y, Ozdemir A, Sayhan S, Gokcu M, Yilmaz B, Sanci M, Inan S, Harma M, Yildirim Y.
    Eur J Obstet Gynecol Reprod Biol; 2014 Aug 15; 179():147-52. PubMed ID: 24965996
    [Abstract] [Full Text] [Related]

  • 15. The use of an immunocytochemical double-labeling staining can display the distribution of Bcl-2/Ki-67 cells in endometrial adenocarcinomas as well as in normal endometrium.
    Mourtzikou A, Kosmas K, Marouga A, Stamouli M, Pouliakis A, Karakitsos P.
    Clin Lab; 2012 Aug 15; 58(1-2):133-44. PubMed ID: 22372356
    [Abstract] [Full Text] [Related]

  • 16. Expression of Ki-67 as proliferation biomarker in imprint smears of endometrial carcinoma.
    Kosmas K, Stamoulas M, Marouga A, Kavantzas N, Patsouris E, Athanassiadou P.
    Diagn Cytopathol; 2013 Mar 15; 41(3):212-7. PubMed ID: 21965052
    [Abstract] [Full Text] [Related]

  • 17. [Molecular action of insulin-sensitizing agents].
    Kacalska O, Krzyczkowska-Sendrakowska M, Milewicz T, Zabińska-Popiela M, Bereza T, Krzysiek-Maczka G, Krzysiek J.
    Endokrynol Pol; 2005 Mar 15; 56(3):308-13. PubMed ID: 16350724
    [Abstract] [Full Text] [Related]

  • 18. Lack of correlation between leptin receptor expression and PI3-K/Akt signaling pathway proteins immunostaining in endometrioid-type endometrial carcinomas.
    Bogusiewicz M, Semczuk A, Gogacz M, Skomra D, Jakowicki JA, Rechberger T.
    Cancer Lett; 2006 Jul 08; 238(1):61-8. PubMed ID: 16085355
    [Abstract] [Full Text] [Related]

  • 19. Metformin inhibits estrogen-dependent endometrial cancer cell growth by activating the AMPK-FOXO1 signal pathway.
    Zou J, Hong L, Luo C, Li Z, Zhu Y, Huang T, Zhang Y, Yuan H, Hu Y, Wen T, Zhuang W, Cai B, Zhang X, Huang J, Cheng J.
    Cancer Sci; 2016 Dec 08; 107(12):1806-1817. PubMed ID: 27636742
    [Abstract] [Full Text] [Related]

  • 20. Chemopreventive effects of metformin on obesity-associated endometrial proliferation.
    Zhang Q, Celestino J, Schmandt R, McCampbell AS, Urbauer DL, Meyer LA, Burzawa JK, Huang M, Yates MS, Iglesias D, Broaddus RR, Lu KH.
    Am J Obstet Gynecol; 2013 Jul 08; 209(1):24.e1-24.e12. PubMed ID: 23500454
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.